Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Dig Dis ; 41(5): 708-718, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36649696

RESUMO

BACKGROUND: One-day low-residue diet (LRD) is recommended before colonoscopy, but only three single-center trials compared the 1-day versus 3-day LRD. The aim of this multicenter study was to compare the impact of a 3-day versus 1-day LRD on its ability to adequately and successfully prepare the bowel of outpatients that require a colonoscopy. The outpatients' tolerance and adherence to the LRD were also considered. METHODS: Consecutive outpatients were randomized to 1-day versus 3-day LRD at three open-access endoscopy units. The primary endpoint consisted of the proportion of patients with a satisfactory degree of bowel cleanliness (Score 2-3 on the Boston Bowel Preparation Scale [BBPS] in each segment). Secondary endpoints were patients' tolerance and adherence to the prescribed diet evaluated by a standardized questionnaire. RESULTS: 289 patients were included in the study (1-day LRD arm = 143, 3-day LRD arm = 146). BBPS ≥2 was not significantly different in the two dietary regimens in any of the three colonic segments (71% vs. 72%, p = 0.9). The percentage of patients with incomplete preparation was similar in the two arms (9% vs. 9%; p = 1.0). No significant differences were found among colonoscopy findings in terms of abnormalities (81% vs. 84%, p = 0.8). Both groups scored similarly in overall tolerance to LRD (48% vs. 49%, p = 1.0) and also in whether they would have adopted a different dietary regimen (p = 0.3). CONCLUSION: Our multicenter randomized study confirmed that optimal bowel cleansing is reached through a 1-day LRD.


Assuntos
Catárticos , Colonoscopia , Humanos , Colo , Dieta , Cuidados Pré-Operatórios , Polietilenoglicóis
2.
Dig Dis Sci ; 56(4): 1188-93, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20859686

RESUMO

BACKGROUND: The influence of aging on video capsule endoscopy (VCE) in obscure gastrointestinal bleeding (OGIB) has never been prospectively assessed. AIMS: To demonstrate if age is a risk factor for incomplete VCE examination in a setting of ongoing hospitalization for OGIB and if it affects the yield of VCE. METHODS: Forty-eight consecutive patients referred to our unit for obscure-overt GI bleeding from March 2007 to September 2009 were prospectively evaluated. Patients were divided into two groups according to their age: ≤65 years (group A) and >65 years (group B). The VCE completion rate and clinically significant findings were studied. RESULTS: The cecum was reached in 73% of patients. There was no difference between the two groups of patients in the VCE completion rate (78% vs. 68%, P=0.4). The overall diagnostic yield was 61%. A significant difference in the diagnostic yield between group A and group B (45% vs. 75%, P=0.04) was shown. Angiodysplasia was diagnosed in 13 out of 24 (54%) patients of group B, whereas mucosal breaks, such as erosions or ulcers, accounted for over a quarter of the group A findings. CONCLUSIONS: Old age is not a risk factor for incomplete VCE examination and it is associated with increased VCE yield.


Assuntos
Endoscopia por Cápsula/métodos , Hemorragia Gastrointestinal/diagnóstico , Fatores Etários , Idoso , Angiodisplasia/diagnóstico , Ceco , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Úlcera Gástrica/diagnóstico
3.
Lancet Gastroenterol Hepatol ; 6(11): 922-932, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34508668

RESUMO

BACKGROUND: Gastrointestinal angiodysplasias are vascular malformations that often cause red blood cell transfusion-dependent anaemia. Several studies suggest that somatostatin analogues might decrease rebleeding rates, but the true effect size is unknown. We therefore aimed to investigate the efficacy of somatostatin analogues on red blood cell transfusion requirements of patients with gastrointestinal angiodysplasias and to identify subgroups that might benefit the most from somatostatin analogue therapy. METHODS: We did a systematic review and individual patient data meta-analysis. We searched MEDLINE, Embase, and Cochrane on Jan 15, 2016, with an updated search on April 25, 2021. All published randomised controlled trials and cohort studies that reported on somatostatin analogue therapy in patients with gastrointestinal angiodysplasias were eligible for screening. We excluded studies without original patient data, single case reports, small case series (ie, <10 participants), studies in which patients had a specific aetiology of gastrointestinal angiodysplasias, and studies in which somatostatin analogue therapy was initiated simultaneously with other treatment modalities. Authors of eligible studies were invited to share individual patient data. Aggregated data was used if individual patient data were not provided. The primary outcome was the mean reduction in the number of red blood cell transfusions during somatostatin analogue therapy, compared with baseline, expressed as the incidence rate ratio (IRR) and absolute mean decrease. We defined patients as either good responders (≥50% reduction in the number of red blood cell transfusions) or poor responders (<50% reduction). A mixed-effects negative binomial regression was used to account for clustering of patients and skewness in data. This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO), number CRD42020213985. FINDINGS: We identified 11 eligible studies (one randomised controlled trial and ten cohort studies) of moderate-to-high quality and obtained individual patient data from the authors of nine (82%) studies. The remaining two (18%) studies provided sufficient information in the published manuscript to extract individual patient data. In total, we analysed data from 212 patients. Somatostatin analogues reduced the number of red blood cell transfusions with an IRR of 0·18 (95% CI 0·14-0·24; p<0·0001) during a median treatment duration of 12 months (IQR 6·0-12·0) and follow-up period of 12 months (12·0-12·0), correlating with a mean absolute decrease in the number of red blood cell transfusions from 12·8 (95% CI 10·4-15·8) during baseline to 2·3 (1·9-2·9) during follow-up-ie, a reduction of 10·5 red blood cell transfusions (p<0·0001). 177 (83%) of 212 patients had a good response to somatostatin analogue therapy (defined as at least a 50% reduction in the number of red blood cell transfusions). Heterogeneity across studies was moderate (I2=53%; p=0·02). Location of gastrointestinal angiodysplasias in the stomach compared with angiodysplasias in the small bowel and colon (IRR interaction 1·92 [95% CI 1·13-3·26]; p=0·02) was associated with worse treatment response. Octreotide was associated with a better treatment response than lanreotide therapy (IRR interaction 2·13 [95% CI 1·12-4·04]; p=0·02). The certainty of evidence was high for the randomised controlled trial and low for the ten cohort studies. Adverse events occurred in 38 (18%) of 212 patients receiving somatostatin analogue therapy, with ten (5%) discontinuing this therapy because of adverse events. The most common adverse events were loose stools (seven [3%] of 212), cholelithiasis (five [2%]), flatulence (four [2%]), and administration site reactions (erythema, five [2%]). INTERPRETATION: Somatostatin analogue therapy is safe and effective in most patients with red blood cell transfusion-dependent bleeding due to gastrointestinal angiodysplasias. Somatostatin analogue therapy is more effective in patients with angiodysplasias located in the small bowel and colon, and octreotide therapy seems to be more effective than lanreotide therapy. FUNDING: The Netherlands Organisation for Health Research and Development and the Radboud University Medical Center.


Assuntos
Angiodisplasia/tratamento farmacológico , Fármacos Gastrointestinais/uso terapêutico , Gastroenteropatias/tratamento farmacológico , Octreotida/uso terapêutico , Peptídeos Cíclicos/uso terapêutico , Somatostatina/análogos & derivados , Angiodisplasia/complicações , Transfusão de Eritrócitos/estatística & dados numéricos , Gastroenteropatias/complicações , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/terapia , Humanos , Somatostatina/uso terapêutico , Resultado do Tratamento
4.
J Mol Med (Berl) ; 85(5): 523-30, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17396241

RESUMO

The endocannabinoid system is upregulated in both human inflammatory bowel diseases and experimental models of colitis. In this study, we investigated whether this upregulation is a marker also of celiac disease-induced atrophy. The levels of the cannabinoid CB(1) receptor, of the endocannabinoids, anandamide, and 2-arachidonoyl-glycerol (2-AG), and of the anti-inflammatory mediator palmitoylethanolamide (PEA) were analyzed in bioptic samples from the duodenal mucosa of celiac patients at first diagnosis assessed by the determination of antiendomysial antibodies and histological examination. Samples were analyzed during the active phase of atrophy and after remission and compared to control samples from non-celiac patients. The levels of anandamide and PEA were significantly elevated (approx. 2- and 1.8-fold, respectively) in active celiac patients and so were those of CB(1) receptors. Anandamide levels returned to normal after remission with a gluten-free diet. We also analyzed endocannabinoid and PEA levels in the jejunum of rats 2, 3, and 7 days after treatment with methotrexate, which causes inflammatory features (assessed by histopathological analyses and myeloperoxidase activity) similar to those of celiac patients. In both muscle/serosa and mucosa layers, the levels of anandamide, 2-AG, and PEA peaked 3 days after treatment and returned to basal levels at remission, 7 days after treatment. Thus, intestinal endocannabinoid levels peak with atrophy and regress with remission in both celiac patients and methotrexate-treated rats. The latter might be used as a model to study the role of the endocannabinoid system in celiac disease.


Assuntos
Moduladores de Receptores de Canabinoides/metabolismo , Doença Celíaca/metabolismo , Duodeno/metabolismo , Endocanabinoides , Jejuno/metabolismo , Receptor CB1 de Canabinoide/metabolismo , Adolescente , Adulto , Amidas , Animais , Ácidos Araquidônicos/metabolismo , Atrofia , Estudos de Casos e Controles , Doença Celíaca/induzido quimicamente , Doença Celíaca/dietoterapia , Doença Celíaca/patologia , Criança , Dieta com Restrição de Proteínas , Modelos Animais de Doenças , Duodeno/patologia , Etanolaminas , Feminino , Glicerídeos/metabolismo , Humanos , Jejuno/patologia , Masculino , Metotrexato , Pessoa de Meia-Idade , Ácidos Palmíticos/metabolismo , Peroxidase/metabolismo , Alcamidas Poli-Insaturadas/metabolismo , Ratos , Ratos Wistar , Fatores de Tempo , Regulação para Cima
5.
FASEB J ; 20(3): 568-70, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16403786

RESUMO

Direct stimulation of cannabinoid CB1 receptors exerts a protective function in animal models of inflammatory bowel diseases (IBDs). However, it is not known whether endocannabinoids are up-regulated during IBDs in animals or humans, nor whether pharmacological elevation of endocannabinoid levels can be exploited therapeutically in these disorders. In this study we addressed these questions. Colon inflammation was induced in mice and rats with 2,4-dinitrobenzene- and 2,4,6-trinitrobenzene sulfonic acids (DNBS and TNBS), respectively. DNBS-treated mice were treated chronically (for 3 or 7 days) with inhibitors of anandamide enzymatic hydrolysis (N-arachidonoyl-serotonin, AA-5-HT) or reuptake (VDM11), 10 or 5 mg/kg, s.c., or with 5-amino-salicilic acid (5-ASA, 1.4 mg/kg, i.r.). Endocannabinoids (anandamide and 2-arachidonoylglycerol, 2-AG) were quantified in mouse colon, or in rat colon mucosa and submucosa, and in bioptic samples from the colon of patients with untreated ulcerative colitis, by liquid chromatography-mass spectrometry. A strong elevation of anandamide, but not 2-AG, levels was found in the colon of DNBS-treated mice, in the colon submucosa of TNBS-treated rats, and in the biopsies of patients with ulcerative colitis. VDM-11 significantly elevated anandamide levels in the colon of DNBS-treated mice and concomitantly abolished inflammation, whereas AA-5-HT did not affect endocannabinoid levels and was significantly less efficacious at attenuating colitis. 5-ASA also increased anandamide levels and abolished colitis. Thus, anandamide is elevated in the inflamed colon of patients with ulcerative colitis, as well as in animal models of IBDs, to control inflammation, and elevation of its levels with inhibitors of its cellular reuptake might be used in the treatment of IBDs.


Assuntos
Ácidos Araquidônicos/biossíntese , Ácidos Araquidônicos/uso terapêutico , Colite/tratamento farmacológico , Mesalamina/uso terapêutico , Receptor CB1 de Canabinoide/fisiologia , Serotonina/análogos & derivados , Adulto , Idoso , Amidoidrolases/antagonistas & inibidores , Animais , Ácidos Araquidônicos/análise , Ácidos Araquidônicos/genética , Ácidos Araquidônicos/farmacologia , Ácidos Araquidônicos/fisiologia , Benzenossulfonatos/toxicidade , Colite/induzido quimicamente , Colite/patologia , Colite Ulcerativa/metabolismo , Colite Ulcerativa/patologia , Colo/química , Colo/patologia , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Endocanabinoides , Feminino , Glicerídeos/análise , Humanos , Doenças Inflamatórias Intestinais/tratamento farmacológico , Doenças Inflamatórias Intestinais/metabolismo , Doenças Inflamatórias Intestinais/patologia , Mucosa Intestinal/química , Mucosa Intestinal/patologia , Masculino , Mesalamina/farmacologia , Camundongos , Camundongos Endogâmicos C57BL , Pessoa de Meia-Idade , Peroxidase/análise , Alcamidas Poli-Insaturadas , Ratos , Ratos Wistar , Receptor CB1 de Canabinoide/agonistas , Serotonina/farmacologia , Serotonina/uso terapêutico , Organismos Livres de Patógenos Específicos , Ácido Trinitrobenzenossulfônico/toxicidade
6.
Eur J Gastroenterol Hepatol ; 18(7): 713-20, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16772827

RESUMO

BACKGROUND AND AIMS: Widespread application of quantitative liver function tests as a prognostic tool is controversial. In this study we assessed the predictivity of serial evaluations of galactose elimination capacity (GEC) and the monoethylglycinexylidide (MEGX) test on survival in viral cirrhosis, and secondarily we compared these tests with Child-Turcotte-Pugh (CTP) and Model for End Stage Liver Disease (MELD) scores. METHODS: In a cohort of 35 patients with viral cirrhosis, GEC and MEGX were evaluated every 6 months for 24 months and compared with CTP and MELD scores at the same time intervals. The end points were patient death or liver transplantation. RESULTS: Statistically significant differences between dead/transplanted patients and survivors were found for basal values of GEC, MEGX, CTP and MELD. Receiver-operating characteristics curves of CTP and MELD scores showed a higher prognostic accuracy than GEC and MEGX. On multivariate analysis, neither GEC nor MEGX were independent predictors of survival. Repeated-measures analysis of GEC and MEGX did not increase the prognostic accuracy of these tests and did not add useful prognostic information on patient outcome during the following 6 months. CONCLUSIONS: Our data suggest that neither single nor repeated determinations of GEC and MEGX are superior to CTP and MELD scores in predicting prognosis of patients with viral cirrhosis.


Assuntos
Hepatite Viral Humana/diagnóstico , Cirrose Hepática/diagnóstico , Testes de Função Hepática/métodos , Adulto , Progressão da Doença , Métodos Epidemiológicos , Feminino , Galactose , Hepatite Viral Humana/fisiopatologia , Humanos , Lidocaína/análogos & derivados , Cirrose Hepática/fisiopatologia , Cirrose Hepática/virologia , Transplante de Fígado , Masculino , Pessoa de Meia-Idade , Prognóstico , Índice de Gravidade de Doença
7.
Infez Med ; 19(3): 176-81, 2011 Sep.
Artigo em Italiano | MEDLINE | ID: mdl-22037438

RESUMO

HPV is a sexually transmitted virus. The main risk factor for infection of the female population is the heterosexual transmission with partners who are infected with human papilloma virus (HPV). HPV infection is very common in sexually active males, and it is the most common STDs. In our experience the prevalence of infection is just under 50%. There are careful and well-established procedures that are applied to women with HPV; on the contrary, with regard to male population, there is, often, less focus and less sensitivity during both diagnostic and therapeutic strategies. The objectives of this study respond to two specific questions: 1. Is it useful to control male partner? 2. What tests are advisable and necessary for a proper definition of the problem? In this study 160 male patients, partners of patients with HPV infection, were examined by peniscopia, the search for HPV-DNA and biopsy of the penis. The study results show that the percentage of HPV infection of the male partners of women with HPV infection is quite high, ranging from 47 to 49% in relation to the methods used. The prevalence of patients with high-risk virus which stands at over 60%. Moreover, from 17.5% to 40.5%, we observed an infection with multiple genotypes of which is known as a hazard factor of aggravation and persistence of HPV infection. In conclusion, HPV-related diseases is a clinical infection of the couple and it is obvious that to the couple should be given great attention. For an important and effective prevention of transmission of HPV from the male subject to viruses to woman, and for the prevention ping-pong effect, it is essential to submit all the male partners of women infected with HPV peniscopia, HPV tests, and possibly a biopsy of the penis.


Assuntos
Alphapapillomavirus/isolamento & purificação , Heterossexualidade , Programas de Rastreamento , Infecções por Papillomavirus/epidemiologia , Adulto , Alphapapillomavirus/genética , Feminino , Humanos , Itália/epidemiologia , Masculino , Infecções por Papillomavirus/diagnóstico , Infecções por Papillomavirus/transmissão , Infecções por Papillomavirus/virologia , Pênis/virologia , Prevalência , Estudos Retrospectivos , Fatores de Risco , Parceiros Sexuais
8.
Neuropharmacology ; 48(8): 1154-63, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15910891

RESUMO

The endogenous cannabimimetic compound, and anandamide analogue, N-palmitoyl-ethanolamine (PEA), was shown to exert potent anti-inflammatory and analgesic effects in experimental models of visceral, neuropathic and inflammatory pain by acting via several possible mechanisms. However, only scant data have been reported on the regulation of PEA levels during pathological conditions in animals or, particularly, humans. We review the current literature on PEA and report the results of three separate studies indicating that its concentrations are significantly increased during three different inflammatory and neuropathic conditions, two of which have been assessed in humans, and one in a mouse model. In patients affected with chronic low back pain, blood PEA levels were not significantly different from those of healthy volunteers, but were significantly and differentially increased (1.6-fold, P<0.01, N=10 per group) 30 min following an osteopathic manipulative treatment. In the second study, the paw skin levels of PEA in mice with streptozotocin-induced diabetic neuropathic pain were found to be significantly higher (1.5-fold, P<0.005, N=5) than those of control mice. In the third study, colonic PEA levels in biopsies from patients with ulcerative colitis were found to be 1.8-fold higher (P<0.05, N=8-10) than those in healthy subjects. These heterogeneous data, together with previous findings reviewed here, substantiate the hypothesis that PEA is an endogenous mediator whose levels are increased following neuroinflammatory or neuropathic conditions in both animals and humans, possibly to exert a local anti-inflammatory and analgesic action.


Assuntos
Moduladores de Receptores de Canabinoides/metabolismo , Colite Ulcerativa/metabolismo , Diabetes Mellitus Experimental/metabolismo , Neuropatias Diabéticas/metabolismo , Inflamação/metabolismo , Dor Lombar/metabolismo , Ácidos Palmíticos/metabolismo , Amidas , Animais , Ensaios Clínicos como Assunto , Endocanabinoides , Etanolaminas , Humanos , Camundongos
9.
Gastroenterology ; 125(3): 677-87, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12949714

RESUMO

BACKGROUND & AIMS: The endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG) inhibit cancer cell proliferation by acting at cannabinoid receptors (CBRs). We studied (1). the levels of endocannabinoids, cannabinoid CB(1) and CB(2) receptors, and fatty acid amide hydrolase (FAAH, which catalyzes endocannabinoid hydrolysis) in colorectal carcinomas (CRC), adenomatous polyps, and neighboring healthy mucosa; and (2). the effects of endocannabinoids, and of inhibitors of their inactivation, on human CRC cell proliferation. METHODS: Tissues were obtained from 21 patients by biopsy during colonoscopy. Endocannabinoids were measured by liquid chromatography-mass spectrometry (LC-MS). CB(1), CB(2), and FAAH expression were analyzed by RT-PCR and Western immunoblotting. CRC cell lines (CaCo-2 and DLD-1) were used to test antiproliferative effects. RESULTS: All tissues and cells analyzed contain anandamide, 2-AG, CBRs, and FAAH. The levels of the endocannabinoids are 3- and 2-fold higher in adenomas and CRCs than normal mucosa. Anandamide, 2-AG, and the CBR agonist HU-210 potently inhibit CaCo-2 cell proliferation. This effect is blocked by the CB(1) antagonist SR141716A, but not by the CB(2) antagonist SR144528, and is mimicked by CB(1)-selective, but not CB(2)-selective, agonists. In DLD-1 cells, both CB(1) and CB(2) receptors mediate inhibition of proliferation. Inhibitors of endocannabinoid inactivation enhance CaCo-2 cell endocannabinoid levels and block cell proliferation, this effect being antagonized by SR141716A. CaCo-2 cell differentiation into noninvasive cells results in increased FAAH expression, lower endocannabinoid levels, and no responsiveness to cannabinoids. CONCLUSIONS: Endocannabinoid levels are enhanced in transformed colon mucosa cells possibly to counteract proliferation via CBRs. Inhibitors of endocannabinoid inactivation may prove useful anticancer agents.


Assuntos
Neoplasias Colorretais/patologia , Ácidos Graxos Insaturados/fisiologia , Amidoidrolases/metabolismo , Células CACO-2 , Moduladores de Receptores de Canabinoides , Diferenciação Celular , Divisão Celular , Neoplasias Colorretais/terapia , Ciclo-Oxigenase 2 , Endocanabinoides , Ácidos Graxos Insaturados/análise , Ácidos Graxos Insaturados/antagonistas & inibidores , Humanos , Isoenzimas/análise , Isoenzimas/antagonistas & inibidores , Proteínas de Membrana , Prostaglandina-Endoperóxido Sintases/análise , Receptores de Canabinoides , Receptores de Droga/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA